首页> 外文期刊>Journal of ocular pharmacology and therapeutics: The official journal of the Association for Ocular Pharmacology and Therapeutics >Influence of Perfluorohexyloctane Eye Drops on Tear Film Thickness in Patients with Mild to Moderate Dry Eye Disease: A Randomized Controlled Clinical Trial
【24h】

Influence of Perfluorohexyloctane Eye Drops on Tear Film Thickness in Patients with Mild to Moderate Dry Eye Disease: A Randomized Controlled Clinical Trial

机译:全氟己基辛烷滴眼液对轻度至中度干眼症患者撕裂膜厚度的影响:随机对照临床试验

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Purpose: The aim of this mechanistic clinical study was to explore the effect of water-free perfluorohexyloctane eye drops on tear film thickness (TFT) in patients with dry eye disease (DED). Methods: Forty-eight patients with mild to moderate DED participated in this randomized, single-masked, observer-blinded parallel group study in a 1:1 ratio to receive either perfluorohexyloctane or unpreserved 0.9% saline solution (Hydrabak (R), Thea, France) eye drops 4 times daily in both eyes for 4 weeks. A custom-built ultrahigh-resolution optical coherence tomography system was used to measure TFT. Furthermore, evaluation of lipid layer thickness (LLT) and noninvasive tear film breakup time, as well as standard clinical tests for signs and symptoms of DED were performed. Results: Mean TFT and LLT at baseline were comparable between the 2 treatment groups. After a single drop instillation, perfluorohexyloctane eye drops temporarily increased TFT immediately. After multiple dosing, perfluorohexyloctane eye drops gradually increased TFT over time with a maximum effect at the end of the study (least square mean difference: 6.42%; P = 0.0142 at week 4). LLT values measured before drop instillation showed a more prominent increase in LLT for perfluorohexyloctane eye drops (13.36% +/- 26.33% vs. 3.21% +/- 28.65%). All other parameters got better in both treatment groups with no statistical difference between groups. Conclusions: These results demonstrate that perfluorohexyloctane eye drops increase TFT as well as LLT over time. These tear film reestablishing attributes are in line with the mode of action of perfluorohexyloctane eye drops to avoid evaporation through stabilization of the lipid layer.
机译:目的:该机制临床研究的目的是探讨无水全氟己基辛烷滴眼液对干眼症(DED)患者撕裂膜厚度(TFT)的影响。方法:48例轻度至中度DED参与该随机,单掩盖,观察者致盲的平行群体1:1的比例接受全氟己基辛烷或未验证的0.9%盐水溶液(Hydrabak(R),TheA,法国)滴眼液每天滴在两只眼中4次4周。使用定制的超高分辨率光学相干断层扫描系统来测量TFT。此外,对脂质层厚度(LLT)和非侵入性撕裂时间的评估以及DED的症状和症状的标准临床试验。结果:2种治疗组之间的基线的平均TFT和LLT可相当。单滴滴注后,全氟己基辛烷滴眼液立即暂时增加TFT。在多次给药后,全氟己基辛烷滴眼液随时间逐渐增加TFT,在研究结束时最大效果(最小二乘差异:6.42%; P = 0.0142,第4周)。在下降滴注之前测量的LLT值表明LLT对全氟己基辛烷眼滴的突出增加(13.36%+/- 26.33%vs.3.21%+/- 28.65%)。两种治疗组中的所有其他参数都在群体之间没有统计学差异。结论:这些结果表明全氟己基辛烷滴眼液随着时间的推移而增加TFT和LLT。这些泪膜重新建立属性符合全氟己基辛烷滴眼液的作用方式,以避免通过脂质层的稳定蒸发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号